Biogen Inc. $BIIB Shares Sold by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. lessened its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 12.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 23,300 shares of the biotechnology company’s stock after selling 3,300 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Biogen were worth $4,101,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of BIIB. Elevation Point Wealth Partners LLC acquired a new stake in shares of Biogen during the second quarter worth $25,000. Accredited Wealth Management LLC boosted its position in shares of Biogen by 1,233.3% in the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 185 shares during the period. WFA of San Diego LLC acquired a new position in shares of Biogen in the 2nd quarter valued at $32,000. True Wealth Design LLC increased its stake in Biogen by 62.9% in the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 90 shares in the last quarter. Finally, GoalVest Advisory LLC purchased a new position in Biogen in the 4th quarter worth about $35,000. 87.93% of the stock is owned by institutional investors.

Biogen Trading Down 3.5%

Shares of NASDAQ BIIB opened at $177.34 on Friday. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. Biogen Inc. has a one year low of $110.04 and a one year high of $202.41. The business has a 50-day moving average price of $186.48 and a two-hundred day moving average price of $171.11. The firm has a market capitalization of $26.03 billion, a PE ratio of 20.13, a PEG ratio of 1.46 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last issued its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. The company had revenue of $2.28 billion for the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The firm’s quarterly revenue was down 7.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, analysts predict that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Biogen news, insider Priya Singhal sold 2,660 shares of the stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the sale, the insider owned 8,043 shares in the company, valued at $1,607,232.69. This represents a 24.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.18% of the company’s stock.

Trending Headlines about Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Acquisition adds approved immunology drugs and revenue: Biogen agreed to acquire Apellis for $5.6B, bringing Syfovre and Empaveli into Biogen’s portfolio and accelerating its push into immunology and rare disease — a clear strategic fit that should boost near-term revenue and pipeline depth. Article Title
• Positive Sentiment: Analysts lift targets and maintain conviction: Multiple firms raised price targets and ratings (Oppenheimer to $275/outperform; Canaccord to $245/buy; HC Wainwright to $237/buy), signaling institutional support for the M&A rationale and longer‑term upside. Article Title Article Title
• Neutral Sentiment: Apellis shares surged on the deal — APLS jumped dramatically (reflecting takeover premium), which is expected after an agreed cash offer but does not directly change Biogen’s near-term cash obligations. Article Title
• Neutral Sentiment: CFO frames deal as debt-neutral/strategic: Biogen’s CFO said combined cash flows and balance-sheet management free capacity for further deals, positioning the company to pursue more early-stage acquisitions. This is strategic context rather than an immediate earnings boost. Article Title
• Neutral Sentiment: Mixed analyst stance: Wedbush raised its price target modestly to $191 but kept a neutral rating, underscoring some caution among analysts despite other upgrades. Article Title
• Negative Sentiment: Investor selling on cash outlay and short-term dilution/near-term risk: Some market participants sold BIIB after the deal announcement, viewing the $5.6B cash use as a near-term headwind despite strategic merits — this is likely the proximate cause of today’s downside. Article Title
• Negative Sentiment: Legal scrutiny on the sale: A plaintiff firm announced an investigation into the adequacy of the Apellis sale price/process, creating a small but nonzero regulatory/legal overhang that could delay or complicate closing. Article Title

Wall Street Analyst Weigh In

BIIB has been the subject of a number of analyst reports. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Biogen in a research note on Monday, February 9th. BMO Capital Markets lifted their target price on shares of Biogen from $165.00 to $196.00 and gave the stock a “market perform” rating in a research report on Friday, February 6th. Guggenheim boosted their price target on shares of Biogen from $185.00 to $246.00 and gave the company a “buy” rating in a report on Monday, February 9th. Morgan Stanley set a $190.00 price target on shares of Biogen in a research report on Sunday, February 8th. Finally, Citigroup raised their price objective on shares of Biogen from $185.00 to $215.00 and gave the stock a “neutral” rating in a research note on Monday, February 9th. Twelve equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $208.31.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.